Department of Pathology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea
© 2015 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest
No potential conflict of interest relevant to this article was reported.
Present case | PEL | HHV8-negative EBL | DLBCL associated with chronic inflammation | |
---|---|---|---|---|
Age at diagnosis | 39 yr | Young or middle-aged | Old (median, 70 yr) | Old (median, 65–70 yr) |
Underlying condition | Pneumocystis jirovecii pneumonia | ND | Fluid overload | Pyothorax or chronic pleuritis |
Site of involvement | Pneumonic bullae | Body cavities | Body cavities | Body cavities |
Immunophenotype | CD20(+), CD79a(+), MUM1(+), CD138(-), CD30(–) | CD20(–), CD79a(–), CD138(+), CD30(+/–) | CD20(+), CD79a(+), CD138(+/–), CD30(+/–) | CD20(+/–), CD79a(+/–), MUM1(+), CD138(+), CD30(+/–) |
Viral infection | HIV(+), HHV8(–) | HIV(+), HHV8(+) | HIV(–), HHV8(–) | HIV(–), HHV8(–) |
EBV(+, latency III), HCV(–) | EBV(+, latency II), HCV(–) | EBV(–), HCV(+, 26.5%) | EBV(+, latency III), HCV(–) | |
Prognosis | Unknown | Unfavorable (median survival, < 6 mo) | Variable (median survival, 10 mo) | Unfavorable (5-yr survival, 20%–35%) |
PEL, primary effusion lymphoma; HHV8, human herpesvirus 8; EBL, effusion-based lymphoma; DLBCL, diffuse large B-cell lymphoma; ND, not described; HIV, human immunodeficiency virus; EBV, Epstein-Barr virus; HCV, hepatitis C virus.